| Literature DB >> 35071836 |
Julianna K Bronk1, Ping Hou2, Mark J Amsbaugh1, Soumen Khatua3, Anita Mahajan4, Leena Ketonen5, Susan L McGovern1.
Abstract
PURPOSE: Diffusion tensor imaging for evaluation of white matter tracts is used with magnetic resonance spectroscopy (MRS) to improve management of diffuse intrinsic pontine glioma (DIPG). Changes in the apparent diffusion coefficient (ADC), fractional anisotropy (FA), and tumor metabolite ratios have been reported after initial radiation for DIPG, but these markers have not been studied sequentially in patients undergoing reirradiation for progressive DIPG. Here, we report a case series of 4 patients who received reirradiation for progressive DIPG on a prospective clinical trial in which we evaluated quantitative changes in FA, ADC, and tumor metabolites and qualitative changes in white matter tracts. METHODS AND MATERIALS: The median reirradiation dose was 25.2 Gy (24-30.8 Gy). Fiber tracking was performed using standard tractography analysis. The FA and ADC values for the corticospinal and medial lemniscus tracts were calculated before and after reirradiation. Multivoxel MRS was performed. Findings were correlated with clinical features and conventional MRI of tumors.Entities:
Year: 2021 PMID: 35071836 PMCID: PMC8763636 DOI: 10.1016/j.adro.2021.100847
Source DB: PubMed Journal: Adv Radiat Oncol ISSN: 2452-1094
Patient characteristics and clinical course
| Patient number | Age at re-RT, y | Sex | Initial dose, Gy | Initial fractions, No. | Time from first RT to re-RT, mo | Re-RT dose, Gy | Re-RT fractions, No. | Time from re-RT to death, mo | Symptoms before re-RT | Symptoms after re-RT | Symptoms at second progression |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | Male | 54 | 30 | 10 | 30.8 | 14 | 6 | Lethargy, weakness, swallowing dysfunction requiring nasogastric tube feeding | Ambulation improved, improved left upper extremity weakness | NA |
| 2 | 6 | Female | 54 | 30 | 10 | 24 | 12 | 4 | Left upper and lower extremity weakness, gait imbalance | Significant improvement in lower extremity strength, left arm mobility, and ability to walk | Increase in left upper and lower extremity weakness; required assistance with walking, broad-based gait |
| 3 | 4 | Male | 54 | 30 | 15 | 24 | 12 | 5 | Left upper extremity weakness, slurred and slow speech; slow, broad-based gait with ataxia | Improvement in speech, steadier gait | Worsened speech and gait; new difficulty swallowing and with eye movements; weakness and rigidity in right hand and foot; dysmetria of the left upper extremity with weakness |
| 4 | 26 | Female | 54 | 30 | 72 | 26.4 | 12 | 21 | Diplopia, ataxia, dysphagia, slurred speech; decreased sensation and movement of right face | Improvement in vision, gait, speech, swallow, and voice; stable numbness and weakness of right face | NA |
Abbreviations: Gy = Gray; NA = not applicable; re-RT = reirradiation.
Fig. 1(A) Diffusion tensor imaging color fractional anisotropy maps and region of interest delineation of the corticospinal (1,2), transverse pontine (3,4), and medial lemniscus (5,6) fibers before and after reirradiation are shown for patient 1. (B) Diffusion tensor imaging tractography of the medical lemniscus tracts before and after reirradiation. T2-FLAIR (C) and T1-post-contrast (D) sequences are shown before reirradiation and after reirradiation.
Tumor size and quantitative DTI analysis
| Patient number | Time from re-RT, mo | Tumor cross-sectional area, cm2 | FA | FA foldchange | ADC × 10–9 m2/s | ADC fold change | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | 0.0 | 1409 | 0.337 | Fold change (progression to response) | 1.35 | Fold change (progression to response) | Progression |
| 0.8 | 1149 | 0.474 | 0.41 | 1.03 | –0.24 | Response | |
| 2 | 0.0 | 1534 | 0.239 | Fold change (progression to response) | 0.88 | Fold change (progression to response) | Progression |
| 1.1 | 1308 | 0.210 | –0.05 | 1.40 | 0.32 | Response | |
| 2.3 | 1319 | 0.244 | Fold change (response to progression) | 0.92 | Fold change (response to progression) | Response | |
| 3.4 | 1438 | 0.118 | –0.48 | 1.71 | 0.48 | Progression | |
| 3 | 0.0 | 1495 | 0.158 | Fold change (progression to response) | 1.36 | Fold change (progression to response) | Progression |
| 1.1 | 1372 | 0.298 | 0.89 | 0.99 | –0.27 | Response | |
| 2.2 | 1625 | 0.193 | Fold change (response to progression) | 0.99 | Fold change (response to progression) | Progression | |
| 4.3 | 1826 | 0.189 | –0.36 | 1.07 | 0.04 | Progression | |
| 4 | 0.0 | 1759 | 0.487 | 1.24 | Progression | ||
| 1.1 | 1583 | 0.589 | 0.98 | Response | |||
| 4.4 | 1555 | 0.541 | 0.92 | Response | |||
| 6.0 | 1415 | 0.500 | Fold change (progression to response) | 1.06 | Fold change (progression to response) | Response | |
| 10.3 | 1266 | 0.600 | 0.14 | 0.91 | –0.22 | Response |
Abbreviations: ADC = apparent diffusion coefficient; DTI = diffusion tensor imaging; FA = fractional anisotropy; re-RT = reirradiation.
Magnetic resonance spectroscopy analysis and enhancement
| Patient number | Time from re-RT, mo | Lipid peak | Cho:Cr | Fold change | Cho:NAA | Fold change | Enhancement | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0 | Yes | 2.8 | Fold change (progression to response) | 1.7 | Fold change (progression to response) | None | Progression |
| 0.8 | Yes, tall | 1.8 | –0.36 | 1.4 | –0.18 | New | Response | |
| 2 | 1.1 | Yes | 2.1 | 2.4 | Stable | Response | ||
| 2.3 | Yes | 3.6 | Fold change (response to progression) | 4.6 | Fold change (response to progression) | Stable | Response | |
| 3.4 | No | 3.9 | 0.37 | 2.8 | –0.20 | Progressive | Progression | |
| 3 | 1.1 | No | 1.7 | 1.1 | Progressive | Response | ||
| 2.2 | Yes | 3.6 | Fold change (response to progression) | 1.6 | Fold change (response to progression) | Progressive | Progression | |
| 4.3 | No | 3.2 | 1.00 | 2.1 | 0.68 | Progressive | Progression | |
| 4 | 1.1 | Yes | 2.5 | 1.2 | New | Response | ||
| 4.4 | No | 4.1 | 1.2 | Decreased | Response | |||
| 10.3 | Yes | 2.5 | 1.6 | None | Response |
Abbreviations: Cho = choline; Cr = creatinine; NAA = N-acetylaspartate; re-RT = reirradiation.
Fig. 2Diffusion tensor imaging tractography of the medial lemniscus tracts in patient 2 (A) and patient 3 (B) are shown before reirradiation, during treatment response, and at second progression. Multivoxel magnetic resonance spectroscopy after re-irradiation (C) and at second progression (D) for patient 3. Decrease in metabolites including N-acetylaspartate (6562-4811) and creatinine (4095-2314) with progression is noted. Likewise, progression of enhancement on T1 postcontrast sequence corresponding to active disease is noted.
Fig. 3Diffusion tensor imaging tractography of the medial lemniscus (A) and corticospinal tracts (B) of patient 4 with sustained response up to 308 days after reirradiation. T2-FLAIR (C) and T1-postcontrast (D) sequences at the level of the pons are shown at each time point.
Abbreviations: ADC = apparent diffusion coefficient; Cho = choline; Cr = creatinine; DTI = diffusion tensor imaging; FA = fractional anisotropy; NAA = N- acetylaspartate.